1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shanghai INT Medical Instruments Co., Ltd. Class H

Shanghai INT Medical Instruments Co., Ltd. Class H

HHKEX:1501
30.18
HKD
-0.42
(-1.37%)
5.22BMarket Cap
Mar 22Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.67
0.86
1.27
1.73
2.16
2.8
3.49
4.43
4.89
6.49
- -
Basic EPS, GAAP
0.25
0.3
0.42
0.67
0.83
0.94
0.86
1.03
1.1
1.33
- -
Free Cash Flow per Basic Share
0.17
0.15
0.13
-0.11
-0.33
-1.39
-0.72
-0.31
0.34
1.42
- -
Dividend per Share
0.08
- -
0.42
0.32
0.18
0.28
0.26
0.24
0.27
- -
- -
Book Value per Share
1
1.25
2.33
7.33
7.87
8.41
9
9.7
10.18
11.45
11.45
Tangible Book Value per Share
1
1.25
2.32
7.08
7.26
7.69
7.98
8.34
8.65
6.61
6.61
Basic Weighted Avg Shares
160
160
160
166
166
166
168
170
174
164
169
Sales/Revenue/Turnover
106
138
203
286
358
465
586
753
852
1,065
- -
Operating Margin (%)
31.82
34.28
31.99
31.49
35.17
24.68
21.02
21.45
25.22
24.28
- -
Depreciation Expense
6
7
11
19
22
30
37
48
80
104
- -
Net Income, GAAP
39
48
66
112
137
156
144
175
192
219
- -
Effective Tax Rate (%)
13.6
14.58
12.39
13.74
15
9.79
7.36
12.51
10.94
9.93
- -
Profit Margin (%)
36.97
34.7
32.74
39.07
38.25
33.51
24.66
23.26
22.53
20.53
- -
Working Capital
128
162
305
1,064
960
705
562
407
458
212
212
LT Debt
- -
- -
55
2
1
13
16
16
16
188
188
Total Equity
159
200
381
1,234
1,328
1,438
1,554
1,678
1,786
2,088
2,088
Return on Invested Capital (%)
- -
22.47
18.5
11.65
9.04
10.07
8.75
9.16
9.98
9.96
- -
Return on Capital (%)
- -
26.54
21.2
13.9
11.07
11.42
9.37
10.73
10.3
8.94
- -
Return on Common Equity (%)
- -
26.54
23.23
14.09
10.87
11.53
9.94
11.08
11.21
11.61
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
228
383
528
LT Borrowings
- -
165
171
LT Finance Leases
16
22
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
174
174
174
Market Capitalization
4,742
3,969
4,694

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
892
869
1,023
Cash, Cash Equivalents & STI
246
491
631
Accounts Receivable, Net
115
86
106
Inventories
162
197
195
Total Current Liabilities
434
696
811
Payables & Accruals
- -
- -
- -
ST Debt
228
383
528
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.54%
16.89%
Free Cash Flow
- -
59.84%
290.44%
Net Income, GAAP
- -
10.23%
14%
Sales/Revenue/Turnover
- -
24.49%
25.06%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
753
2024
- -
- -
852
2025
- -
- -
1,065

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.03
2024
- -
- -
1.1
2025
- -
- -
1.33

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.24
2024
- -
- -
0.27
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dong Ke Liang
Full Time Employees
2,088
Sector
Health technology
Industry
Medical specialties
Address
No. 925 Jin Yuan Yi Road Shanghai SH China 201803
IPO Date
Nov 8, 2019
Website
kdl-int.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shanghai INT Medical Instruments Co., Ltd. (formerly Shanghai Kindly Medical Instruments Co., Ltd.) engages in the research, development, manufacture, and sale of cardiovascular interventional medical devices and related accessories. Founded in 2006 and headquartered in Shanghai, China, the company offers a comprehensive portfolio including digital inflation devices, cardiac valve balloon inflation catheters, guiding catheters, micro catheters, guidewires, angiography catheters, Y-connector packs, manifolds, pressure bandages, angiography syringes, stopcocks, Seldinger needles, pressure transducers, extension tubes, introducer sets, joint intervention kits, distal access catheters, ureteral access sheaths, pressure-controlled suction systems, endoscopic visualization systems, single-use digital flexible ureteroscopes, arterial hemostasis bandages, and cardiovascular guidewires; it also provides medical accessories such as check valves, needle-free connectors, male Luer locks, bi-stoppers, Heparin caps, flush devices, flow regulators, and drip chamber assemblies, alongside other products like disposable respirators, 3D surgical face masks, vaginal dilators, Foley catheters, infusion pumps, umbilical cord clamps, and burette infusion sets. The company operates primarily in mainland China, with exports to Europe, the United States, and over 70 other countries and regions, serving cardiology, neurology, ENT, orthopedics, urology, regenerative aesthetics, and focused ultrasound therapy segments through 16 subsidiaries. In January 2024, the company changed its name from Shanghai Kindly Medical Instruments Co., Ltd. to Shanghai INT Medical Instruments Co., Ltd. to reflect its strategic evolution; it recently signed an agreement to acquire an additional 20% stake in Shanghai Pukon Medical Instruments Co., Ltd., entered a partnership agreement for the Huaige Guangtai Fund targeting life sciences investments, and established the Chengdu Huaige Fund with Huaige Health, while reporting revenue growth to approximately RMB585.88 million for the year ended December 31, 2022, driven by expanded distribution networks and agent business. As a leading Chinese player with complete industry chain capabilities including mold development, equipment design, and sterilization, the company holds 73 NMPA certificates, 36 CE certificates, 18 FDA certificates, 334 authorized patents, and maintains ISO13485 certification, positioning it for growth in DRG/DIP payment modes and global markets.